These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7864692)

  • 1. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy.
    Gardner-Medwin JM; Smith NJ; Powell RJ
    Ann Rheum Dis; 1994 Dec; 53(12):828-32. PubMed ID: 7864692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients].
    de Wazières B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL
    Rev Med Interne; 1999 Jul; 20(7):567-70. PubMed ID: 10434346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide in severe orogenital ulceration.
    Jenkins JS; Powell RJ; Allen BR; Littlewood SM; Maurice PD; Smith NJ
    Lancet; 1984 Dec; 2(8417-8418):1424-6. PubMed ID: 6151044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behçet's disease in UK children: clinical features and treatment including thalidomide.
    Kari JA; Shah V; Dillon MJ
    Rheumatology (Oxford); 2001 Aug; 40(8):933-8. PubMed ID: 11511764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial.
    Davies UM; Palmer RG; Denman AM
    Br J Rheumatol; 1988 Aug; 27(4):300-2. PubMed ID: 3044474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
    Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H
    Ann Intern Med; 1998 Mar; 128(6):443-50. PubMed ID: 9499327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
    Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
    N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
    Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
    Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of recurrent oro-genital ulceration with low doses of thalidomide.
    De Wazières B; Gil H; Vuitton DA; Dupond JL
    Clin Exp Rheumatol; 1999; 17(3):393. PubMed ID: 10410284
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigation and treatment of orogenital ulceration; studies on a possible mode of action of thalidomide.
    Powell RJ; Allen BR; Jenkins JS; Steele L; Hunneyball I; Maurice PD; Littlewood SM
    Br J Dermatol; 1985 Jul; 113 Suppl 28():141-4. PubMed ID: 4040386
    [No Abstract]   [Full Text] [Related]  

  • 11. Thalidomide neuropathy in patients treated for metastatic prostate cancer.
    Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD
    Muscle Nerve; 2001 Aug; 24(8):1050-7. PubMed ID: 11439380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide, orogenital ulcers, and the risk of teratogenesis.
    Lehner T; Sullivan FM
    Lancet; 1985 Feb; 1(8423):288-9. PubMed ID: 2857357
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of thalidomide on orogenital ulceration.
    Bowers PW; Powell RJ
    Br Med J (Clin Res Ed); 1983 Sep; 287(6395):799-800. PubMed ID: 6412834
    [No Abstract]   [Full Text] [Related]  

  • 14. Thalidomide in gastrointestinal disorders.
    Bousvaros A; Mueller B
    Drugs; 2001; 61(6):777-87. PubMed ID: 11398909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind trial of depot corticosteroids in Behçet's syndrome.
    Mat C; Yurdakul S; Uysal S; Gogus F; Ozyazgan Y; Uysal O; Fresko I; Yazici H
    Rheumatology (Oxford); 2006 Mar; 45(3):348-52. PubMed ID: 16263779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study.
    Alpsoy E; Er H; Durusoy C; Yilmaz E
    Arch Dermatol; 1999 May; 135(5):529-32. PubMed ID: 10328192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab treatment for severe orogenital ulceration in Behçet's disease.
    Connolly M; Armstrong JS; Buckley DA
    Br J Dermatol; 2005 Nov; 153(5):1073-5. PubMed ID: 16225632
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Behçet's disease with thalidomide.
    Hamza MH
    Clin Rheumatol; 1986 Sep; 5(3):365-71. PubMed ID: 3780143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
    Kocer B; Sucak G; Kuruoglu R; Aki Z; Haznedar R; Erdogmus NI
    Acta Neurol Belg; 2009 Jun; 109(2):120-6. PubMed ID: 19681443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.